- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline
Richard W. Joseph, MD, discusses how the use of predictive biomarkers can either be beneficial to patients who have the markers, or disadvantageous to those who do not have the markers but may still reap some benefit from a targeted agent, such as in the case of PD-1 inhibitors and PD-L1 expression. How a targeted therapy can and will be prescribed is affected by how a therapy is positioned in a practice algorithm, as well as by coverage decisions made by the pharmaceutical and therapeutic committees.
Ira M. Klein, MD, MBA, FACP, expresses his frustration with payments being misaligned with outcomes versus value. Joseph concurs and describes key factors the healthcare system should focus on besides costs, including quality of life and treatment delivery processes.
Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
